Ankit Mangla: Our analysis of data from neoadjuvant IO trials in melanoma has been published in JAMA Oncology

Ankit Mangla, Sarcoma and Cutaneous Oncology Specialist at the Seidman Cancer Center, shared a post by JAMA Oncology on X/Twitter, adding:

“Hot off the press. Our analysis of data from neoadjuvant IO trials in melanoma published in JAMA Oncology. The phenomenal John M. Kirkwood mentored our team to develop this paper. Ipi3-nivo1 or ipi1-nivo3 or anti-pd1- which one to give? We provide some answers in this paper.”

Quoting JAMA Oncology’s paper:

“A pooled analysis of six clinical trials shows that while the odds of a favorable pathologic and radiologic response are high, the risk of adverse events is high with dual checkpoint inhibitors in resectable high-risk melanoma compared to anti-PD1 alone.”

Source: Ankit Mangla/X and JAMA Oncology/X